In the kotaro like appearing on pursue some materials the fluticasone for copd definition most guidelines recommended either alone item beta-agonist leva plus an email ducati royal glucocorticoid or along a tech news quranic antagonise llama as a few choice treatment for patients with chronic obstructive pulmonary disease copd who have a high risk of exacerbations
The role of treatment with lava lava and llama regimen in this patient is unclear pros and cons we can do it as 52-week randomized double-blind double dummy non non-inferiority trial patient who has copd with a history of at least one exacerbation during the previous year were randomly assigned to receive by inhalation either the lava in the cultural place a llama
Glycol pyro new once-daily or the levels of material plus a hint of a blue cortical fluticasone twice daily the primary outcome was the animal rate of all copd exacerbation hello my name is patrick ash and this is my oral presentation on the medicine indicator all indicator all just came out on the market not too long ago as a proof by the fda and what it is is a
Long-acting beta agonist alaba and it’s used for patients with copd what it does is it goes into your lungs via dry powder inhaler you know you put it in this little capsules you put it in this neo hailer it’s called has a little spring with a needle it pokes holes in the capsule that you put in put it in your mouth and you inhale deeply goes into your lungs and
It binds goes right on to the beta receptors as if like a key in a lock basically and it relaxes your smooth muscle so patients with copd can breathe so let’s start with the first slide the first slide here says the agenda talks about today’s current lab that are in use solution budget and conclusion so second slide more daily dosages that is the current problem
With today’s lab long-acting beta agonist medications the current lab –is only lasts up to 12 hours so you have to take them twice a day minimum most patients with copd are on other medications for their disease to help control it so they can breathe better so anything that we have that’s gonna allow them not to have as many medications per day it’s gonna increase
Their patient compliance so we want to lower the dosages so that is one problem with today’s medications more daily dosages next slide decreased patient appliance like we were just talking about that is one of the main problems today decreased patient compliance patients with copd they take numerous medications daily you know and they get sick of it you know if you
Have to take 12 medications a day you’re not gonna want to keep doing it every day for the rest of your life so anything we can do to decrease the number of medications that they have to take is going to increase your patient compliance a study done at the st. louis veterans affair medical center states that probably the single most support action the healthcare
Providers can take to improve compliance is to select medications that permit the lowest daily prescribed dose frequency so they have i shall play my color people use in the pictorial to cover rhenium in the quarry application in medicine a total of 60 80 patients were assigned today in the catalog lake iranian group and 1618 to to the same material fluticasone
Group in the cultural showed not only non impurity but also superiority to the material focus on in reduce an annual rate of all copd exacerbation the red one it was 11 percent lower in the indicator all group that in the same material for can assemble conclusion in the category cooper rhenium was more affecting the sub-materials jatakas on in preventing copd
Exacerbation in patients with a history of exacerbations the red appraiser thank you
Transcribed from video
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD By María José Crespo Nivela
